lymph node-targeted platform
Amplifying the immune response
to defeat solid tumors
lymph node-targeted platform
Amplifying the immune response
to defeat solid tumors
lymph node-targeted platform
Amplifying the immune response
to defeat solid tumors
At Elicio, we engineer cancer immunotherapies that harness the natural power of our immune system
Our targeted-delivery approach generates robust immune responses that activate and amplify cancer-fighting T cells, potentially setting patients up to fight aggressive tumors with success.
One platform, vast possibilities for cancer treatment
We develop next-generation vaccines, immunomodulators, and adjuvants that are built with our AMP platform. Our goal is to defeat the most challenging cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC).
A dynamic powerhouse of immuno-oncology experts
With expertise in materials science, immunology, and cancer therapy, we bring together the best as we forge a new path forward.